liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Safe and effective conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009.
(University Hospital Maastricht)
(University Medical Centre Groningen)
Linköping University, Department of Medicine and Health Sciences, Cardiology . Östergötlands Läns Landsting, Heart Centre, Department of Cardiology. Linköping University, Faculty of Health Sciences.ORCID iD: 0000-0003-3059-4404
(Grochowski Hospital)
Show others and affiliations
2006 (English)In: Heart Rhythm, ISSN 1547-5271, Vol. 3, no 11, 1321-1331 p.Article in journal (Refereed) Published
Abstract [en]


Acute drug conversion of persistent atrial fibrillation usually fails.


The purpose of this study was to test the proarrhythmic potential, safety, and efficacy of the novel antiarrhythmic agent AZD7009 in patients with persistent atrial fibrillation (AF) or atrial flutter (mean duration 43 days) scheduled for direct current (DC) cardioversion.


Patients were randomized to AZD7009 (3-hour intravenous infusion; n = 86) or placebo (n = 36). AZD7009 was given in doses intended to produce target pseudo–steady-state plasma levels of 0.25, 0.50, 0.75, 1.0, 1.5, 2.0, or 2.5 μmol/L after 30 minutes of infusion. DC cardioversion was performed if conversion to sinus rhythm (SR) did not occur within 2 hours of infusion.


AZD7009 in a concentration-dependent manner increased the rate of conversion of AF to SR and shortened the time to conversion. At the three highest target concentrations of AZD7009, 45%, 64%, and 70% of AF patients converted after a mean time of 62, 55, and 26 minutes, respectively, whereas no placebo-treated patients converted. SR was maintained for 24 hours in 21 of 22 patients with drug-associated conversion. AZD7009 treatment was associated with QT-interval prolongation; the increase in QT corrected according to Fridericia typically ranged from 40 to 80 ms at targeted pseudo–steady-state plasma concentrations ≥0.75 μmol/L, but a number of outliers with QT corrected according to Fridericia >550 ms were seen in the higher concentration groups, particularly after conversion to SR and prolonged infusion. None of the patients exhibited torsades de pointes according to predefined criteria; however, one patient exhibited a nonsustained, polymorphic ventricular tachycardia of eight beats with torsades de pointes–like features after AZD7009 infusion (asymptomatic and discovered only upon retrospective Holter tape analysis). Clinical adverse events (primarily dizziness, bradycardia, hypotension, and nausea) were significantly more common in the highest target concentration AZD7009 group vs placebo (P <.001).


AZD7009 exhibited dose-dependent effects in converting AF to SR in AF patients and appeared to be associated with a low risk of proarrhythmia despite continued administration during a period of heightened vulnerability.

Place, publisher, year, edition, pages
2006. Vol. 3, no 11, 1321-1331 p.
Keyword [en]
Antiarrhythmic drug; Atrial fibrillation; Atrial flutter; AZD7009; Proarrhythmia; Sinus rhythm
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-21381DOI: 10.1016/j.hrthm.2006.06.035OAI: diva2:241158
Available from: 2009-10-01 Created: 2009-10-01 Last updated: 2013-12-17

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Walfridsson, Håkan
By organisation
Cardiology Department of CardiologyFaculty of Health Sciences
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 25 hits
ReferencesLink to record
Permanent link

Direct link